CN101522658A - 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐 - Google Patents

作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐 Download PDF

Info

Publication number
CN101522658A
CN101522658A CNA2007800302762A CN200780030276A CN101522658A CN 101522658 A CN101522658 A CN 101522658A CN A2007800302762 A CNA2007800302762 A CN A2007800302762A CN 200780030276 A CN200780030276 A CN 200780030276A CN 101522658 A CN101522658 A CN 101522658A
Authority
CN
China
Prior art keywords
compound
metformin
lipoate
dimethylbiguanide
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800302762A
Other languages
English (en)
Chinese (zh)
Inventor
B·L·迈拉里
N·E·瓦曼劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indigene Pharmaceuticals Inc
Original Assignee
Indigene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indigene Pharmaceuticals Inc filed Critical Indigene Pharmaceuticals Inc
Publication of CN101522658A publication Critical patent/CN101522658A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800302762A 2006-06-16 2007-06-14 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐 Pending CN101522658A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81425006P 2006-06-16 2006-06-16
US60/814,250 2006-06-16

Publications (1)

Publication Number Publication Date
CN101522658A true CN101522658A (zh) 2009-09-02

Family

ID=38669506

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800302762A Pending CN101522658A (zh) 2006-06-16 2007-06-14 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐

Country Status (10)

Country Link
US (1) US7973073B2 (https=)
EP (1) EP2046773A1 (https=)
JP (1) JP2009541220A (https=)
CN (1) CN101522658A (https=)
AR (1) AR061500A1 (https=)
CA (1) CA2691775A1 (https=)
CL (1) CL2007001759A1 (https=)
IL (1) IL195959A0 (https=)
TW (1) TW200816986A (https=)
WO (1) WO2007149313A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110037998A (zh) * 2018-01-16 2019-07-23 镇学初 二甲双胍盐在治疗脑梗死中的用途
CN110294738A (zh) * 2019-07-22 2019-10-01 通化师范学院 硫辛酸衍生物及其制备方法和用途

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8102027B2 (en) * 2007-08-21 2012-01-24 Broadcom Corporation IC package sacrificial structures for crack propagation confinement
WO2009111037A2 (en) * 2008-03-04 2009-09-11 Indigene Pharmaceuticals Inc. Compositions and methods for treating nos-associated diseases
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
AU2008357111B2 (en) * 2008-06-26 2013-05-09 Laboratorios Silanes, S.A. De C.V. A new metformin Glycinate salt for blood glucose control
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
WO2010047717A1 (en) * 2008-10-24 2010-04-29 Biolink Life Sciences, Inc. Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
EP3069612A3 (en) 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
WO2010147962A1 (en) 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
WO2011130719A2 (en) 2010-04-15 2011-10-20 The Regents Of The University Of Michigan A biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8440723B2 (en) * 2011-05-11 2013-05-14 Banavara L. Mylari Metformin salts of salicylic acid and its congeners
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
CA2941518A1 (en) 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
CA2947741A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
MX392359B (es) * 2017-11-17 2025-03-24 Cellix Bio Private Ltd Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas
SG11202004019SA (en) 2017-11-17 2020-05-28 Cellix Bio Private Ltd Compositions and methods for the treatment of eye disorders
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085498A1 (en) 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
FR2796551B1 (fr) 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
WO2003068209A1 (en) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110037998A (zh) * 2018-01-16 2019-07-23 镇学初 二甲双胍盐在治疗脑梗死中的用途
CN110294738A (zh) * 2019-07-22 2019-10-01 通化师范学院 硫辛酸衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CL2007001759A1 (es) 2008-10-24
WO2007149313A1 (en) 2007-12-27
EP2046773A1 (en) 2009-04-15
JP2009541220A (ja) 2009-11-26
US7973073B2 (en) 2011-07-05
US20070293562A1 (en) 2007-12-20
AR061500A1 (es) 2008-09-03
TW200816986A (en) 2008-04-16
IL195959A0 (en) 2009-09-22
CA2691775A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
CN101522658A (zh) 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
AU2012205547B2 (en) Lipid-lowering antidiabetic agent
JP5810084B2 (ja) 一酸化窒素生成調節剤
WO2003068209A1 (en) Metformin salts of lipophilic acids
EA022890B1 (ru) Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения
US9707196B2 (en) Treatment agent and/or prophylactic agent for side effects of cancer drugs
CN111840561B (zh) S100a9抑制剂在制备治疗胰腺炎的药物中的应用
US8853259B2 (en) Metformin derivatives for treating diabetes and diabetes complications
TW516959B (en) Composition containing ascorbic acid
JPH01221329A (ja) 悪性腫瘍の診断の間、その腫瘍を対照するための組成物
CN105001195A (zh) R(+)-硫辛酸-l-赖氨酸盐的新晶型及其制备方法
CN102351881B (zh) 一种稳定的盐酸左氧氟沙星化合物
AU749673B2 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
JPS62164626A (ja) 降圧および利尿剤
CN115919831B (zh) 苯甲酸酯类化合物在抑制尿酸转运体蛋白1的活性及制备治疗高尿酸血症的药物中的应用
HK1137446A (en) Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
CN114835767A (zh) 一种熊果苷偶联物及其应用
CN121588096A (zh) 青蒿琥酯在制备防治缺铁性贫血药物及保健品中的应用
RU2457202C1 (ru) Производное 3-(2,2,2-триметилгидразиний)пропионата - 5- гидрокисиникотинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью
CN1628795A (zh) 一种治疗心脑血管疾病的制剂及其制备方法和质量控制方法
TW202033199A (zh) 化合物ａ與化合物ｂ聯合在製備治療痛風或高尿酸血症的藥物中的用途
EA012378B1 (ru) 1-дезокси-1-n-метиламмония-d-глюцитола сукцинат
HUE029259T2 (en) Method and composition for iron administration
TW200529808A (en) Quinone series pulmonary disease
HK1196003A (en) Treatment agent and/or prophylactic agent for side effects of cancer drugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1137446

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090902

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1137446

Country of ref document: HK